Jupiter Topco LLC Buys New Position in Omeros Corporation $OMER

Jupiter Topco LLC bought a new position in Omeros Corporation (NASDAQ:OMER) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 30,500 shares of the biopharmaceutical company’s stock, valued at approximately $290,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Ancora Advisors LLC acquired a new stake in shares of Omeros during the 2nd quarter worth approximately $1,605,000. Legal & General Group Plc acquired a new stake in Omeros in the second quarter worth $425,000. The Manufacturers Life Insurance Company bought a new stake in Omeros in the second quarter valued at $180,000. Compass Financial Management LLC acquired a new position in shares of Omeros during the second quarter valued at about $312,000. Finally, BlackRock Inc. bought a new position in shares of Omeros during the 2nd quarter worth about $57,484,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OMER shares. Weiss Ratings upgraded Omeros from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, September 3rd. Zacks Research cut Omeros from a “strong-buy” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Omeros Stock Performance

OMER stock opened at $19.12 on Wednesday. The business has a 50-day simple moving average of $13.89 and a two-hundred day simple moving average of $12.39. The company has a market capitalization of $1.38 billion, a P/E ratio of 14.94 and a beta of 2.60. Omeros Corporation has a 52-week low of $3.94 and a 52-week high of $19.65.

Omeros (NASDAQ:OMER) last posted its earnings results on Thursday, August 13th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.29. The company had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. As a group, sell-side analysts forecast that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO David J. Borges sold 10,000 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $18.95, for a total transaction of $189,500.00. Following the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at approximately $111,918.70. The trade was a 62.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Thomas J. Cable sold 15,000 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $18.45, for a total transaction of $276,750.00. Following the completion of the sale, the director directly owned 35,067 shares of the company’s stock, valued at $646,986.15. The trade was a 29.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 95,906 shares of company stock valued at $1,780,205 in the last 90 days. Insiders own 10.50% of the company’s stock.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.